GlassScriptPhysician profile
Madeleine Vy Tran
NPI 1154192599
$5,213.47
in general payments reported to CMS, 2019-2025
31 companies · $2,628 in 2025
The $2,628 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $19.50 · 2024: $2,566 · 2025: $2,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,213.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $796.24 | 2024-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $643.26 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $469.02 | 2023-2025 | |
| Novo Nordisk INC | $426.04 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $324.06 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $310.05 | 2024-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $301.27 | 2024-2025 | |
| Abbvie INC. | $232.19 | 2024-2025 | |
| Lilly USA, LLC | $217.22 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Baxter Healthcare | $201.05 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.69 | 2024-2025 | Jardiance |
| Shield Therapeutics INC | $158.80 | 2024-2025 | |
| Verona Pharma, INC. | $137.77 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $115.96 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $99.42 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $84.19 | 2024-2025 | Immunocap |
| Astellas Pharma US INC | $77.90 | 2024-2025 | Veozah |
| Viatris Specialty LLC | $51.09 | 2025 | Yupelri |
| Ferring Pharmaceuticals INC. | $50.85 | 2025 | Euflexxa |
| Abbott Laboratories | $41.16 | 2024-2025 | Freestyle Libre, Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $39.33 | 2024 | Aptima |
| Bioventus LLC | $30.22 | 2024 | Supartz Fx Sodium Hyaluronate |
| Organon LLC | $30.16 | 2025 | Nexplanon |
| Mylan Specialty L.P. | $29.95 | 2024 | Yupelri |
| Rgh Enterprises LLC | $25.61 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $24.74 | 2025 | |
| Agios Pharmaceuticals, INC. | $23.85 | 2024 | Pyrukynd |
| Scilex Pharmaceuticals INC. | $23.84 | 2025 | |
| Viiv Healthcare Company | $23.42 | 2024 | Apretude |
| Otsuka America Pharmaceutical, INC. | $20.67 | 2025 | Rexulti |
| Tempus Ai, INC | $15.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeleine Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.